Semi-Annual Report (Unaudited)

CHINA UNIVERSAL INTERNATIONAL ETF SERIES – C-SHARES CSI HEALTHCARE INDEX ETF

(A Sub-Fund of China Universal International ETF Series, an umbrella unit trust established under the laws of Hong Kong)

For the period from 1 January 2016 to 30 June 2016



(A Sub-Fund of China Universal International ETF Series)

CONTENTS

	Pages
MANAGEMENT AND ADMINISTRATION	1
STATEMENT OF FINANCIAL POSITION	2
STATEMENT OF COMPREHENSIVE INCOME	3
STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO UNITHOLDERS	4

STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO UNITHOLDERS	4
INVESTMENT PORTFOLIO (UNAUDITED)	5 - 7
MOVEMENTS IN INVESTMENT PORTFOLIO (UNAUDITED)	8 - 10
PERFORMANCE RECORD (UNAUDITED)	11

(A Sub-Fund of China Universal International ETF Series)

MANAGEMENT AND ADMINISTRATION

MANAGER AND RQFII HOLDER

China Universal Asset Management (Hong Kong) Company Limited 3710-11, Two International Finance Centre 8 Finance Street Central Hong Kong

DIRECTORS OF THE MANAGER

LI Wen WAN Qing ZHANG Hui

ADVISER

China Universal Asset Management Company Limited 22/F, Aurora Plaza No. 99 Fucheng Road Pudong District Shanghai 200120 China

RQFII CUSTODIAN

Bank of China Limited No. 1, Fuxingmen Nei Dajie Beijing 100818 China

LEGAL ADVISER TO THE MANAGER

Deacons 5th Floor, Alexandra House 18 Chater Road Central Hong Kong

SERVICE AGENT OR CONVERSION AGENT

HK Conversion Agency Services Limited 2nd Floor, Infinitus Plaza 199 Des Voeux Road Central Hong Kong

AUDITORS

Ernst & Young 22/F, CITIC Tower 1 Tim Mei Avenue Central Hong Kong

TRUSTEE

BOCI-Prudential Trustee Limited 12/F & 25/F, Citicorp Centre 18 Whitfield Road Causeway Bay Hong Kong

CUSTODIAN

Bank of China (Hong Kong) Limited 14/F, Bank of China Tower 1 Garden Road Central Hong Kong

REGISTRAR

Computershare Hong Kong Investor Services Limited 46th Floor, Hopewell Centre 183 Queen's Road East Wan Chai Hong Kong

(A Sub-Fund of China Universal International ETF Series)

STATEMENT OF FINANCIAL POSITION

	30 June 2016 RMB (Unaudited)	31 December 2015 RMB (Audited)
ASSETS Financial assets at fair value through profit or loss Prepayment and other receivables Cash and bank balances Deposit reserve-China Exchange Clearing	32,572,178 6,589 917,374 8,046	
TOTAL ASSETS	33,504,187	40,356,251
LIABILITIES Trustee and custodian fees payable Withholding tax provision Other payables and accruals	10,000 164 138,610	3,396 10,072
TOTAL LIABILITIES	148,774	227,000
EQUITY NET ASSETS ATTRIBUTABLE TO UNITHOLDERS	33,355,413	40,129,251
NUMBER OF UNITS IN ISSUE	2,100,000	2,100,000
NET ASSET VALUE PER UNIT	15.8835	19.1092

(A Sub-Fund of China Universal International ETF Series)

STATEMENT OF COMPREHENSIVE INCOME

	For the period from 1 January 2016 to 30 June 2016	For the period from 1 January 2015 to 30 June 2015
	RMB (Unaudited)	RMB (Unaudited)
INCOME Dividend income Interest income	177,301 665 177,966	206,862 3,066 209,928
EXPENSES Management fee Brokerage commission Trustee and custodian fees Auditors' remuneration Index licensing fee Professional fee Other operating expenses	(3,441) (30,841) (93,623) (50,000) (78,724) (130,328) (386,957)	(81,719) (50,000)
(LOSS) BEFORE INVESTMENT AND EXCHANGE DIFFERENCES	(208,991)	(279,913)
INVESTMENT AND EXCHANGE DIFFERENCES Net change in unrealised (losses)/gains on financial assets at fair value through profit or loss Net realised (losses)/gains on financial assets at fair value through profit or loss NET INVESTMENTS AND EXCHANGE (LOSSES)/GAINS	(5,721,650) (814,725) (6,536,375)	2,388,995
(LOSS)/PROFIT BEFORE TAX	(6,745,366)	9,656,154
Withholding tax	(28,472)	(23,859)
(LOSS)/PROFIT AFTER TAX AND TOTAL COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD	(6,773,838)	9,632,295

(A Sub-Fund of China Universal International ETF Series)

STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO UNITHOLDERS

	For the period from 1 January 2015 to 30 June 2015
	RMB (Unaudited)
At 31 December 2014 & 1 January 2015	21,263,043
Subscription of units	48,246,939
Redemption of units	(21,941,523)
Total comprehensive income for the period	9,632,295
At 30 June 2015	57,200,754
	For the period from 1 January 2016 to 30 June 2016
	1 January 2016
At 31 December 2015 & 1 January 2016	1 January 2016 to 30 June 2016 RMB
At 31 December 2015 & 1 January 2016 Subscription of units	1 January 2016 to 30 June 2016 RMB (Unaudited)
	1 January 2016 to 30 June 2016 RMB (Unaudited)
Subscription of units	1 January 2016 to 30 June 2016 RMB (Unaudited)

(A Sub-Fund of China Universal International ETF Series)

INVESTMENT PORTFOLIO (Unaudited)

As at 30 June 2016

	Holdings Shares	Market Value RMB	% of NAV
Financial assets at fair value through profit or loss			
Listed Securities			
China (100%)			
Health Care			
AIER EYE HOSPITAL GROUP CO LTD-A	17,164	627,001	1.88%
BEIJING SL PHARMACEUTICAL CO LTD-A	17,928	541,067	1.62%
BEIJING TIANTAN BIOLOGICAL PRODUCTS CORP LTD-A	11,200	311,248	0.93%
BEIJING TONGRENTANG CO LTD-A	29,547	880,205	2.64%
CHANGCHUN HIGH & NEW TECHNOLOGY INDUSTRIES			
(GROUP) INC-A	5,980	637,947	1.91%
CHINA ANIMAL HUSBANDRY INDUSTRY CO LTD-A	9,100	166,530	0.50%
CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL			
CO LTD-A	15,738	286,746	0.86%
CHINA RESOURCES SANJIU MEDICAL &			
PHARMACEUTICAL CO LTD-A	17,100	414,162	1.24%
DA AN GENE CO LTD SUN YAT-SEN UNIVERSITY-A	22,154	615,881	1.85%
GUANGDONG ZHONGSHENG PHARMACEUTICAL CO			
LTD-A	19,300	231,407	0.69%
GUANGXI WUZHOU ZHONGHENG GROUP CO LTD-A	109,500	475,230	1.42%
GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HLDGS		,	
CO LTD-A	23,400	576,576	1.73%
GUIZHOU BAILING GROUP PHARMACEUTICAL CO LTD-	,	,	
А	18,200	313,040	0.94%
GUIZHOU XINBANG PHARMACEUTICAL CO LTD-A	29,400	271,656	0.81%
GUIZHOU YIBAI PHARMACEUTICAL CO LTD-A	25,400	405,892	1.22%
HAINAN HAIYAO CO LTD-A	38,074	415,387	1.25%
HARBIN GLORIA PHARMACEUTICALS CO LTD-A	38,931	338,700	1.02%
HARBIN PHARMACEUTICAL GROUP CO LTD-A	64,400	533,876	1.60%
HEILONGJIANG ZBD PHARMACEUTICAL CO LTD-A	7,200	157,320	0.47%
HUALAN BIOLOGICAL ENGINEERING INC-A	20,256	636,038	1.91%
HUMANWELL HEALTHCARE GROUP CO LTD-A	39,180	657,049	1.97%
HYBIO PHARMACEUTICAL CO LTD-A	19,400	394,790	1.18%
JIANGSU HENGRUI MEDICINE CO LTD-A	62,620	2,511,688	7.53%
JIANGSU KANION PHARMACEUTICAL CO LTD-A	18,600	303,738	0.91%
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO			
LTD-A	12,600	399,672	1.20%
JIANGZHONG PHARMACEUTICAL CO LTD-A	7,800	248,040	0.74%
JILIN AODONG MEDICINE INDUSTRY GROUPS CO LTD-A	30,828	769,159	2.31%
JILIN ZIXIN PHARMACEUTICAL INDUSTRIAL CO LTD-A	11,200	164,640	0.49%
JINLING PHARMACEUTICAL CO LTD-A	13,100	171,479	0.51%
JINYU BIO-TECHNOLOGY CO LTD-A	25,004	683,359	2.05%
JOINCARE PHARMACEUTICAL GROUP INDUSTRY CO	7	· ·	
LTD-A	28,300	259,794	0.78%
KUNMING PHARMACEUTICAL CORP-A	24,200	330,088	0.99%
	,	1	

(A Sub-Fund of China Universal International ETF Series)

INVESTMENT PORTFOLIO (Unaudited) (Continued)

As at 30 June 2016

	Holdings Shares	Market Value RMB	% of NAV
Financial assets at fair value through profit or loss			
(Continued)			
Listed Securities			
China (100%)			
Health Care (Continued)			
LEPU MEDICAL TECHNOLOGY BEIJING CO LTD-A	37,600	685,824	2.06%
LIVZON PHARMACEUTICAL GROUP INC-A	5,480	252,683	0.76%
MAYINGLONG PHAHRMACEUTICAL GROUP CO LTD-A	13,000	270,790	0.81%
NORTH CHINA PHARMACEUTICAL CO LTD-A	35,200	218,592	0.66%
SHANDONG DONG-E E-JIAO CO LTD-A	22,435	1,185,241	3.55%
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD-A	49,800	947,196	2.84%
SHANGHAI HAIXIN GROUP CO-A	31,800	423,258	1.27%
SHANGHAI KAIBAO PHARMACEUTICAL CO LTD-A	21,560	219,265	0.66%
SHANGHAI KEHUA BIO-ENGINEERING CO LTD-A	17,891	381,257	1.14%
SHANGHAI KINGSTAR WINNING SOFTWARE CO LTD-A	24,500	605,150	1.81%
SHANGHAI RAAS BLOOD PRODUCTS CO LTD-A	23,904	900,703	2.70%
SHENZHEN GLORY MEDICAL CO LTD-A	9,538	222,999	0.67%
SHENZHEN HEPALINK PHARMACEUTICAL CO LTD-A	16,800	293,328	0.88%
SHENZHEN SALUBRIS PHARMACEUTICALS CO LTD-A	13,700	372,640	1.12%
SHIJIANGZHUANG YILING PHARMACEUTICAL CO LTD-A	19,600	311,836	0.93%
SHINVA MEDICAL INSTRUMENT CO LTD-A	12,400	286,316	0.86%
SICHUAN KELUN PHARMACEUTICAL CO LTD-A	37,502	577,906	1.73%
TASLY PHARMACEUTICAL GROUP CO LTD-A	28,000	1,001,280	3.00%
TIANJIN CHASE SUN PHARMACEUTICAL CO LTD-A	22,400	389,536	1.17%
TIANJIN ZHONGXIN PHARMACEUTICAL GROUP CORP			
LTD-A	10,000	172,700	0.52%
TONGHUA DONGBAO PHARMACEUTICAL CO LTD-A	41,520	859,049	2.58%
XIANGXUE PHARMACEUTICAL CO LTD-A	20,580	303,143	0.91%
YABAO PHARMACEUTICAL GROUP CO LTD-A	24,130	242,024	0.73%
YUNNAN BAIYAO GROUP CO LTD-A	22,500	1,446,750	4.34%
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO			
LTD-A	13,000	585,130	1.75%
ZHEJIANG CONBA PHARMACEUTICAL CO LTD-A	55,755	361,292	1.08%
ZHEJIANG DIAN DIAGNOSTICS CO LTD-A	14,100	465,018	1.39%
ZHEJIANG HISUN PHARMACEUTICAL CO LTD-A	22,115	268,697	0.81%
ZHEJIANG HUAHAI PHARMACEUTICAL CO LTD-A	27,040	657,613	1.97%
ZHEJIANG MEDICINE CO LTD-A	28,300	373,277	1.12%
ZHEJIANG NHU CO LTD-A	23,696	500,697	1.50%
ZHEJIANG XIANJU PHARMACEUTICAL CO LTD-A	16,415	183,848	0.55%
ZHONGYUAN UNION CELL & GENE ENGINEERING CORP	10 750	102 215	1 4504
LTD-A	13,752	483,245	1.45%

(A Sub-Fund of China Universal International ETF Series)

INVESTMENT PORTFOLIO (Unaudited) (Continued)

As at 30 June 2016

	Holdings Shares	Market Value RMB	% of NAV
Financial assets at fair value through profit or loss			
(Continued) Listed Securities China (100%)			
Health Care (Continued)			
ZHUHAI HOKAI MEDICAL INSTRUMENTS CO LTD-A	20,600	394,490	1.18%
TOTAL INVESTMENTS, AT FAIR VALUE	_	32,572,178	97.65%
TOTAL INVESTMENTS, AT COST	_	38,518,665	

(A Sub-Fund of China Universal International ETF Series)

MOVEMENTS IN INVESTMENT PORTFOLIO (Unaudited)

For the period from 1 January 2016 to 30 June 2016

	Holdings As at 1 January 2016	Additions	Corporate Action	Disposals	Holdings As at 30 June 2016
Financial assets at fair value through profit or loss					
Listed Securities					
AIER EYE HOSPITAL GROUP CO LTD-A BEIJING SL PHARMACEUTICAL CO LTD-A BEIJING TIANTAN BIOLOGICAL PRODUCTS	17,164 17,928	-	-	-	17,164 17,928
CORP LTD-A	11,900	-	-	(700)	11,200
BEIJING TONGRENTANG CO LTD-A	30,147	-	_	(600)	29,547
CHANGCHUN HIGH & NEW TECHNOLOGY INDUSTRIES (GROUP) INC-A CHANGCHUN HIGH & NEW TECHNOLOGY	4,600	1,380	-	-	5,980
INDUSTRIES (GROUP) INC-A-RTS (EX 27APR2016) CHINA ANIMAL HUSBANDRY INDUSTRY CO	-	1,380	-	(1,380)	-
LTD-A	9,100	-	_	-	9,100
CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO LTD-A CHINA RESOURCES SANJIU MEDICAL &	15,738	-	-	-	15,738
PHARMACEUTICAL CO LTD-A CHONGQING ZHIFEI BIOLOGICAL PRODUCTS	17,100	-	-	-	17,100
CO LTD-A DA AN GENE CO LTD SUN YAT-SEN	13,900	-	13,900	(27,800)	-
UNIVERSITY-A GUANGDONG ZHONGSHENG	20,140	-	2,014	-	22,154
PHARMACEUTICAL CO LTD-A GUANGXI WUZHOU ZHONGHENG GROUP CO	19,300	-	-	-	19,300
LTD-A GUANGZHOU BAIYUNSHAN	109,500	-	-	-	109,500
PHARMACEUTICAL HLDGS CO LTD-A	23,400	-	-	-	23,400
GUIZHOU BAILING GROUP PHARMACEUTICAL CO LTD-A	-	18,200	-	-	18,200
GUIZHOU XINBANG PHARMACEUTICAL CO					
LTD-A	32,600	-	-	(3,200)	29,400
GUIZHOU YIBAI PHARMACEUTICAL CO LTD-A	25,400	-	-	-	25,400
HAINAN HAIYAO CO LTD-A	19,037	-	19,037	-	38,074
HAISCO PHARMACEUTICAL GROUP CO LTD-A HARBIN GLORIA PHARMACEUTICALS CO LTD-	11,160	-	-	(11,160)	-
A	12,977	-	25,954	-	38,931
HARBIN PHARMACEUTICAL GROUP CO LTD-A HEILONGJIANG ZBD PHARMACEUTICAL CO	44,000	7,200	13,200	-	64,400
LTD-A	3,600	-	3,600	-	7,200
HENGKANG MEDICAL GROUP CO LTD-A	44,750	-	-	(44,750)	-
HUALAN BIOLOGICAL ENGINEERING INC-A	12,660	-	7,596	-	20,256

8

(A Sub-Fund of China Universal International ETF Series)

MOVEMENTS IN INVESTMENT PORTFOLIO (Unaudited) (continued)

For the period from 1 January 2016 to 30 June 2016

	Holdings As at 1 January 2016	Additions	Corporate Action	Disposals	Holdings As at 30 June 2016
<u>Financial assets at fair value through profit or loss</u> (continued) Listed Securities					
HUBEI JUMPCAN PHARMACEUTICAL CO LTD-					
А	7,200	-	-	(7,200)	-
HUMANWELL HEALTHCARE GROUP CO LTD-A HUNAN ER-KANG PHARMACEUTICAL CO LTD-	39,180	-	-	-	39,180
A	15,900	-	15,900	(31,800)	-
HYBIO PHARMACEUTICAL CO LTD-A	19,400	-	-	-	19,400
JIANGSU HENGRUI MEDICINE CO LTD-A JIANGSU KANION PHARMACEUTICAL CO LTD-	51,012	1,900	10,120	(412)	62,620
A	16,085	-	3,100	(585)	18,600
JIANGSU YUYUE MEDICAL EQUIPMENT &			5,100	. ,	
SUPPLY CO LTD-A	12,950	-	-	(350)	12,600
JIANGZHONG PHARMACEUTICAL CO LTD-A JILIN AODONG MEDICINE INDUSTRY GROUPS	8,302	-	-	(502)	7,800
CO LTD-A	31,228	-	-	(400)	30,828
JILIN ZIXIN PHARMACEUTICAL INDUSTRIAL	11 200				11 200
COLTD-A	11,200	-	-	-	11,200
JINLING PHARMACEUTICAL CO LTD-A	13,900	-	-	(800)	13,100
JINYU BIO-TECHNOLOGY CO LTD-A JOINCARE PHARMACEUTICAL GROUP	25,004	-	-	-	25,004
INDUSTRY CO LTD-A	28,300	-	-	-	28,300
KUNMING PHARMACEUTICAL CORP-A LEPU MEDICAL TECHNOLOGY BEIJING CO	12,100	-	12,100	-	24,200
LTD-A	21,200		18,800	(2,400)	37,600
LID-A LIVZON PHARMACEUTICAL GROUP INC-A	5,480	-	10,000	(2,400)	5,480
MAYINGLONG PHAHRMACEUTICAL GROUP		-	-	-	
CO LTD-A	13,570	-	-	(570)	13,000
NORTH CHINA PHARMACEUTICAL CO LTD-A	37,420	-	-	(2,220)	35,200
RENHE PHARMACY CO LTD-A	37,775	-	-	(37,775)	-
SHANDONG DONG-E E-JIAO CO LTD-A SHANGHAI FOSUN PHARMACEUTICAL GROUP	22,435	-	-	-	22,435
CO LTD-A	49,800	-	-	-	49,800
SHANGHAI HAIXIN GROUP CO-A SHANGHAI KAIBAO PHARMACEUTICAL CO	-	31,800	-	-	31,800
LTD-A SHANGHAI KEHUA BIO-ENGINEERING CO LTD-	22,960	-	-	(1,400)	21,560
А	17,891	-	-	-	17,891
SHANGHAI KINGSTAR WINNING SOFTWARE CO LTD-A	-	24,500	-	-	24,500
SHANGHAI RAAS BLOOD PRODUCTS CO LTD-A	23,904	-	-	-	23,904

(A Sub-Fund of China Universal International ETF Series)

MOVEMENTS IN INVESTMENT PORTFOLIO (Unaudited) (continued)

For the period from 1 January 2016 to 30 June 2016

	Holdings As at 1 January 2016	Additions	Corporate Action	Disposals	Holdings As at 30 June 2016
Financial assets at fair value through profit or loss					
(continued)					
Listed Securities					
SHENZHEN GLORY MEDICAL CO LTD-A SHENZHEN HEPALINK PHARMACEUTICAL CO	9,538	-	-	-	9,538
LTD-A	10,500	-	6,300	-	16,800
SHENZHEN SALUBRIS PHARMACEUTICALS CO					
LTD-A SHIJIANGZHUANG YILING PHARMACEUTICAL	13,700	-	-	-	13,700
CO LTD-A	19,600	-	-	-	19,600
SHINVA MEDICAL INSTRUMENT CO LTD-A SICHUAN KELUN PHARMACEUTICAL CO LTD-	12,400	-	-	-	12,400
A	37,502	-	-	-	37,502
TASLY PHARMACEUTICAL GROUP CO LTD-A	28,400	-	-	(400)	28,000
TIANJIN CHASE SUN PHARMACEUTICAL CO LTD-A	17 400	5 000			22 400
TIANJIN TIANYAO PHARMACEUTICAL CO LTD-	17,400	5,000	-	-	22,400
A	26,500	-	-	(26,500)	-
TIANJIN ZHONGXIN PHARMACEUTICAL	_ = , = = = =			(;)	
GROUP CORP LTD-A	10,000	-	-	-	10,000
TONGHUA DONGBAO PHARMACEUTICAL CO					
LTD-A	34,600	-	6,920	-	41,520
XIANGXUE PHARMACEUTICAL CO LTD-A	20,580	-	-	-	20,580
YABAO PHARMACEUTICAL GROUP CO LTD-A	24,130	-	-	-	24,130
YUNNAN BAIYAO GROUP CO LTD-A ZHANGZHOU PIENTZEHUANG	22,605	-	-	(105)	22,500
PHARMACEUTICAL CO LTD-A	8,918	-	4,459	(377)	13,000
ZHEJIANG CONBA PHARMACEUTICAL CO LTD-	0,710		т,т.) /	(377)	15,000
A	28,970	12,300	14,485	-	55,755
ZHEJIANG DIAN DIAGNOSTICS CO LTD-A	6,000	3,300	4,800	-	14,100
ZHEJIANG HISUN PHARMACEUTICAL CO LTD-					
А	22,115	-	-	-	22,115
ZHEJIANG HUAHAI PHARMACEUTICAL CO					
LTD-A	20,800	-	6,240	-	27,040
ZHEJIANG MEDICINE CO LTD-A	30,100	-	-	(1,800)	28,300
ZHEJIANG NHU CO LTD-A	23,696	-	-	-	23,696
ZHEJIANG XIANJU PHARMACEUTICAL CO LTD-A	16 /15				16 / 15
ZHONGYUAN UNION CELL & GENE	16,415	-	-	-	16,415
ENGINEERING CORP LTD-A	11,952	2,100	-	(300)	13,752
ZHUHAI HOKAI MEDICAL INSTRUMENTS CO	11,202	-,100		(200)	,
LTD-A	20,600	-	-	-	20,600

(A Sub-Fund of China Universal International ETF Series)

PERFORMANCE RECORD (Unaudited)

1. NET ASSET VALUE

	Net asset value per unit RMB	Total net asset value RMB
As at 30 June 2016	15.8835	33,355,413
As at 31 December 2015	19.1092	40,129,251
As at 31 December 2014 ¹	14.1754	21,263,043
¹ Year of inception		

2. HIGHEST ISSUE AND LOWEST REDEMPTION PRICES PER UNIT

	Highest issue unit price RMB	Lowest redemption unit price RMB
For the period from 1 January 2016 to 30 June 2016	17.8182	14.2021
Year ended 31 December 2015	26.4732	14.7146
For the period from 5 May 2014 (date of inception) to 31 December 2014	15.4367	12.0133